β受体阻滞剂在日常心血管治疗中的真正作用。
The Real Role of β-Blockers in Daily Cardiovascular Therapy.
机构信息
Department of Cardiology, Petz Aladár County Teaching Hospital, Vasvári Pál str. 2-4, 9024, Győr, Hungary.
出版信息
Am J Cardiovasc Drugs. 2017 Oct;17(5):361-373. doi: 10.1007/s40256-017-0221-8.
Abstract
The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, β-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the respective medical societies for heart failure, coronary artery disease, and atrial fibrillation as well as in hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. When indicated, cardioselective β-blockers should be prescribed in patients with diabetes mellitus or chronic obstructive pulmonary disease. We review the available evidence for the use of β-blockers in clinical conditions in which recommendations can be made for everyday practice.
摘要
β-受体阻滞剂（β 阻滞剂）在心血管治疗中的作用在过去几十年中经历了多种趋势和变化。随着各种治疗高血压的优秀药物的出现，β 阻滞剂已从原发性高血压的一线治疗药物中降级。然而，它们仍然是相关医学协会推荐用于心力衰竭、冠心病和心房颤动以及高血压合并心力衰竭、心绞痛或既往心肌梗死的首选药物。在有指征的情况下，应在患有糖尿病或慢性阻塞性肺疾病的患者中开具有心脏选择性的β 阻滞剂。我们回顾了在有推荐意见的临床情况下使用β 阻滞剂的可用证据，以指导日常实践。
相似文献
1
The Real Role of β-Blockers in Daily Cardiovascular Therapy.β受体阻滞剂在日常心血管治疗中的真正作用。
Am J Cardiovasc Drugs. 2017 Oct;17(5):361-373. doi: 10.1007/s40256-017-0221-8.
2
Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus.β受体阻滞剂在今日高血压治疗中的地位：印度共识。
J Assoc Physicians India. 2024 Oct;72(10):83-90. doi: 10.59556/japi.72.0715.
3
Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study.β受体阻滞剂在心力衰竭和慢性阻塞性肺疾病患者中的选择和可互换性：一项意大利基于登记的队列研究。
Sci Rep. 2019 Aug 7;9(1):11465. doi: 10.1038/s41598-019-47967-y.
4
The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues.β 受体阻滞剂在心力衰竭合并症患者中的应用：疑问、确定和未解决的问题。
Eur J Intern Med. 2021 Jun;88:9-14. doi: 10.1016/j.ejim.2021.03.035. Epub 2021 Apr 30.
5
Differences in betablocking drugs in cardiovascular therapy.心血管治疗中β受体阻滞剂药物的差异。
Ann Clin Res. 1988;20(5):324-33.
6
The effects of newer beta-adrenoceptor antagonists on vascular function in cardiovascular disease.新型β肾上腺素能受体拮抗剂对心血管疾病血管功能的影响。
Curr Vasc Pharmacol. 2012 May;10(3):378-90. doi: 10.2174/157016112799959323.
7
The foundation role of beta blockers across the cardiovascular disease spectrum: a year 2009 update.β受体阻滞剂在心血管疾病谱中的基础作用：2009 年更新。
Am J Med. 2010 Nov;123(11):S2. doi: 10.1016/j.amjmed.2010.08.003.
8
9
[Comparison beta-blockers and their relevance to pharmacologic therapy of cardiovascular diseases].[β受体阻滞剂及其与心血管疾病药物治疗的相关性比较]
Arzneimittelforschung. 2002;52(2):73-80. doi: 10.1055/s-0031-1299860.
10
Use of beta-blockers in atrial fibrillation.β受体阻滞剂在心房颤动中的应用。
Am J Cardiovasc Drugs. 2002;2(1):37-42. doi: 10.2165/00129784-200202010-00005.
引用本文的文献
1
Optimizing Cardiovascular Outcomes With Bisoprolol: An Evidence-Based Perspective.从循证角度看比索洛尔对心血管结局的优化作用
Cureus. 2025 Aug 7;17(8):e89579. doi: 10.7759/cureus.89579. eCollection 2025 Aug.
2
Beta-Blockers and mortality in patients with malignancy and cardiovascular disease: an analysis of the MIMIC-IV database.β受体阻滞剂与恶性肿瘤合并心血管疾病患者的死亡率：MIMIC-IV数据库分析
BMC Cancer. 2025 Aug 21;25(1):1351. doi: 10.1186/s12885-025-14745-1.
3
Impact of Genetic Variation in Adrenergic Receptors on β-Blocker Effectiveness and Safety in Cardiovascular Disease Management: A Systematic Review.肾上腺素能受体基因变异对心血管疾病管理中β受体阻滞剂有效性和安全性的影响：一项系统评价
Pharmaceuticals (Basel). 2025 Mar 28;18(4):493. doi: 10.3390/ph18040493.
4
Evaluation of a Specialist Nurse-Led Post-Coronary Heart Disease Support Program: A Prospective Pre-Post Interventional Study.一项由专科护士主导的冠心病后支持项目的评估：一项前瞻性干预前后研究。
Healthcare (Basel). 2024 Dec 11;12(24):2497. doi: 10.3390/healthcare12242497.
5
Systemic hypertension in adults with congenital heart diseases.先天性心脏病成人患者的系统性高血压
Int J Cardiol Congenit Heart Dis. 2023 Apr 6;13:100456. doi: 10.1016/j.ijcchd.2023.100456. eCollection 2023 Sep.
6
A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.慢性阻塞性肺疾病急性加重住院患者基于证据的7点出院护理方案：共识策略与专家建议
NPJ Prim Care Respir Med. 2024 Dec 20;34(1):44. doi: 10.1038/s41533-024-00378-7.
7
Association between comorbid COPD or chronic bronchitis and the prognosis of patients with Dilated cardiomyopathy.合并 COPD 或慢性支气管炎与扩张型心肌病患者预后的关系。
Ann Med. 2024 Dec;56(1):2428857. doi: 10.1080/07853890.2024.2428857. Epub 2024 Nov 16.
8
Beta-Blockers of Different Generations: Features of Influence on the Disturbances of Myocardial Energy Metabolism in Doxorubicin-Induced Chronic Heart Failure in Rats.不同代的β受体阻滞剂：对阿霉素诱导的大鼠慢性心力衰竭中心肌能量代谢紊乱的影响特征
Biomedicines. 2024 Aug 28;12(9):1957. doi: 10.3390/biomedicines12091957.
9
A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies.心血管疾病管理的综合述评：心脏生物标志物、成像方式、药物治疗、手术干预和草药疗法。
Cells. 2024 Sep 1;13(17):1471. doi: 10.3390/cells13171471.
10
Nonadherence to Cardiovascular Drugs Predicts Risk for Non-Arthritic Anterior Ischemic Optic Neuropathy: A Large-Scale National Study.心血管药物治疗依从性不佳预示非关节炎性前部缺血性视神经病变风险：一项大规模全国性研究
J Clin Med. 2024 Aug 9;13(16):4670. doi: 10.3390/jcm13164670.
本文引用的文献
1
Decreased Mortality With Beta-Blockers in Patients With Heart Failure and Coexisting Atrial Fibrillation: An AF-CHF Substudy.β受体阻滞剂降低心力衰竭合并心房颤动患者的死亡率：AF-CHF 亚组研究。
JACC Heart Fail. 2017 Feb;5(2):99-106. doi: 10.1016/j.jchf.2016.10.015. Epub 2017 Jan 11.
2
Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet.心力衰竭合并心房颤动：β受体阻滞剂仍有用武之地。
JACC Heart Fail. 2017 Feb;5(2):107-109. doi: 10.1016/j.jchf.2016.12.003. Epub 2017 Jan 11.
3
Evaluating the effectiveness of different beta-adrenoceptor blockers in heart failure patients.评估不同β-肾上腺素能受体阻滞剂对心力衰竭患者的疗效。
Int J Cardiol. 2017 Mar 1;230:378-383. doi: 10.1016/j.ijcard.2016.12.098. Epub 2016 Dec 21.
4
Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative.β受体阻滞剂治疗与慢性阻塞性肺疾病和心力衰竭或左心室功能障碍患者心肌梗死后死亡率的关系：来自高危心肌梗死数据库倡议的倾向匹配队列分析。
Eur J Heart Fail. 2017 Feb;19(2):271-279. doi: 10.1002/ejhf.647. Epub 2016 Oct 24.
5
Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.心力衰竭和慢性阻塞性肺疾病中β受体阻滞剂的使用不足。
Heart. 2016 Dec 1;102(23):1909-1914. doi: 10.1136/heartjnl-2016-309458. Epub 2016 Jul 5.
6
Carvedilol, Bisoprolol, and Metoprolol Use in Patients With Coexistent Heart Failure and Chronic Obstructive Pulmonary Disease.卡维地洛、比索洛尔和美托洛尔在合并心力衰竭和慢性阻塞性肺疾病患者中的应用
Medicine (Baltimore). 2016 Feb;95(5):e2427. doi: 10.1097/MD.0000000000002427.
7
Predictors of Atrial Fibrillation Recurrence in Hyperthyroid and Euthyroid Patients.甲状腺功能亢进和甲状腺功能正常患者心房颤动复发的预测因素
Arq Bras Cardiol. 2016 Feb;106(2):84-91. doi: 10.5935/abc.20160013. Epub 2016 Jan 26.
8
Does Oral Beta-Blocker Therapy Improve Long-Term Survival in ST-Segment Elevation Myocardial Infarction With Preserved Systolic Function? A Meta-Analysis.口服β受体阻滞剂治疗能否改善收缩功能保留的ST段抬高型心肌梗死患者的长期生存率？一项荟萃分析。
J Cardiovasc Pharmacol Ther. 2016 May;21(3):280-5. doi: 10.1177/1074248415608011. Epub 2015 Sep 29.
9
Rate-control treatment and mortality in atrial fibrillation.房颤的心率控制治疗与死亡率。
Circulation. 2015 Oct 27;132(17):1604-12. doi: 10.1161/CIRCULATIONAHA.114.013709. Epub 2015 Sep 17.
10
Pharmacological and emerging therapies in the treatment of chronic angina.治疗慢性稳定型心绞痛的药理学和新兴治疗方法。
Lancet. 2015 Aug 15;386(9994):691-701. doi: 10.1016/S0140-6736(15)61283-1.
Zotero 插件